Evidence map›Paper›PMID 37211857›Full record

ArticleThe Prostate2023

Evaluation of a photodynamic therapy agent using a canine prostate cancer model.

Dong Luo, Xinning Wang, Gopalakrishnan Ramamurthy, Ethan Walker, Lifang Zhang, Aditi Shirke, Naraen G Naidu, Clemens Burda, Reena Shakya, Eric T Hostnik and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Prostate, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Applications of AuNanomaterials (Basel, Switzerland) · 2024
    Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Dong LuoDepartment of Radiology, Case Western Reserve University, Cleveland, Ohio, USA.
Xinning WangDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0001-7729-0534
Gopalakrishnan RamamurthyDepartment of Radiology, Case Western Reserve University, Cleveland, Ohio, USA.
Ethan WalkerDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Lifang ZhangDepartment of Radiology, Case Western Reserve University, Cleveland, Ohio, USA.
Aditi ShirkeDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Naraen G NaiduDepartment of Radiology, Case Western Reserve University, Cleveland, Ohio, USA.
Clemens BurdaDepartment of Chemistry, Case Western Reserve University, Cleveland, Ohio, USA.
Reena ShakyaTarget Validation Shared Resource, James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.
Eric T HostnikDepartment of Veterinary Clinical Sciences, College of Veterinary Medicine-Veterinary Medical Center, The Ohio State University, Columbus, Ohio, USA.
Mathew JosephInterventional Cardiology Cath Core Lab, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA.
Lee PonskyDepartment of Urology, University Hospitals, Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio, USA.
Vladimir PonomarevDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Thomas J RosolDepartment of Biomedical Sciences, Ohio University, Athens, Ohio, USA.
Michael F TweedleDepartment of Radiology, The Wright Center for Innovation in Biomolecular Imaging, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0001-7319-2400
James P BasilionDepartment of Radiology, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-8659-3307
Case Western Reserve University · USCenter for Innovation · USLung Institute · USMemorial Sloan Kettering Cancer Center · USOhio University · USTarget (United States) · USThe Ohio State University · USUniversity Hospitals of Cleveland · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell TherapyR01CA204924 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2016 to 2020
$3.5M
Theranostic gold nanoparticles for imaged-guided radical prostatectomy and PDT ablationR01EB020353 · NIBIB · CASE WESTERN RESERVE UNIVERSITY · PI BASILION, JAMES PETER · 2016 to 2019
$2.7M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204924NIBIB NIH HHS R01 EB020353NIH HHS
6 · The paper itself

Abstract

backgroundMale dogs can develop spontaneous prostate cancer, which is similar physiologically to human disease. Recently, Tweedle and coworkers have developed an orthotopic canine prostate model allowing implanted tumors and therapeutic agents to be tested in a more translational large animal model. We used the canine model to evaluate prostate-specific membrane antigen (PSMA)-targeted gold nanoparticles as a theranostic approach for fluorescence (FL) imaging and photodynamic therapy (PDT) of early stage prostate cancer.

methodsDogs (four in total) were immunosuppressed with a cyclosporine-based immunosuppressant regimen and their prostate glands were injected with Ace-1-hPSMA cells using transabdominal ultrasound (US) guidance. Intraprostatic tumors grew in 4-5 weeks and were monitored by ultrasound (US). When tumors reached an appropriate size, dogs were injected intravenously (iv) with PSMA-targeted nano agents (AuNPs-Pc158) and underwent surgery 24 h later to expose the prostate tumors for FL imaging and PDT. Ex vivo FL imaging and histopathological studies were performed to confirm PDT efficacy.

resultsAll dogs had tumor growth in the prostate gland as revealed by US. Twenty-four hours after injection of PSMA-targeted nano agents (AuNPs-Pc158), the tumors were imaged using a Curadel FL imaging device. While normal prostate tissue had minimal fluorescent signal, the prostate tumors had significantly increased FL. PDT was activated by irradiating specific fluorescent tumor areas with laser light (672 nm). PDT bleached the FL signal, while fluorescent signals from the other unexposed tumor tissues were unaffected. Histological analysis of tumors and adjacent prostate revealed that PDT damaged the irradiated areas to a depth of 1-2 mms with the presence of necrosis, hemorrhage, secondary inflammation, and occasional focal thrombosis. The nonirradiated areas showed no visible damages by PDT.

conclusionWe have successfully established a PSMA-expressing canine orthotopic prostate tumor model and used the model to evaluate the PSMA-targeted nano agents (AuNPs-Pc158) in the application of FL imaging and PDT. It was demonstrated that the nano agents allowed visualization of the cancer cells and enabled their destruction when they were irradiated with a specific wavelength of light.

Indexed as

Antineoplastic AgentsMetal NanoparticlesPhotochemotherapyProstatic NeoplasmsAnimalsCell Line, TumorDogsGoldHumansMaleProstateAntineoplastic AgentsGoldcanine prostate cancerfluorescence imagingnanoparticlesPDTPSMA

Identifiers

PMID37211857
PMCPMC11135201
OpenAlexW4377220851

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.